SCHEMBL17156646

SCHEMBL17156646

COC(=O)c1cnc(Cl)cc1Nc1cc(C)ccc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ HTT P42858 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ CLCN2 P51788 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ HPGD P15428 1/20 0.40
▸ CYP46A1 Q9Y6A2 1/20 0.39
▸ PTGS2 P35354 1/20 0.39
▸ LMNA P02545 2/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ JAK2 O60674 3/20 0.38
▸ JAK1 P23458 3/20 0.38
▸ TYK2 P29597 3/20 0.38
▸ JAK3 P52333 3/20 0.38
▸ PDK1 Q15118 1/20 0.38
▸ PDK2 Q15119 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17134620 0.90 CLCN2 (0.41) MAPTALDH1A1HTTMEN1NPC1
SCHEMBL17134686 0.80 ALDH1A1 (0.47) MAPTALDH1A1MEN1NPC1RAB9A
SCHEMBL17156862 0.80 LMNA (0.45) MAPTALDH1A1MEN1KMT2ATP53
SCHEMBL30824147 0.78 MAPK13 (0.43) MAPTALDH1A1KMT2A
SCHEMBL24550087 0.78 MAPK13 (0.43) MAPTALDH1A1KMT2A
SCHEMBL17119640 0.76 SMARCA2 (0.43) MAPTALDH1A1MEN1KMT2ACYP46A1
SCHEMBL17134862 0.76 CLCN2 (0.52) MEN1NPC1RAB9AKMT2ACLCN2
SCHEMBL7569086 0.76 KDM4E (0.46) MAPTALDH1A1HTTLMNAMAPK1
SCHEMBL17156659 0.76 NR4A2 (0.48) MAPTALDH1A1HTTMEN1NPC1
SCHEMBL5624190 0.75 MAP2K2 (0.50) MAPTALDH1A1MEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2930170-B1 PYRIDONE COMPOUND FOR USE IN THE TREATMENT OF DERMATOLOGICAL DISORDERS KYOWA KIRIN CO LTD (JP) 2020-02-05 — — EP disclosed
US-9643952-B2 Pyridone compound KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-05-09 — — US disclosed
US-20150315172-A1 PYRIDONE COMPOUND KYOWA KIRIN CO., LTD. (JP) 2015-11-05 — — US disclosed
EP-2930170-A1 PYRIDONE COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2015-10-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150315172-A1 PYRIDONE COMPOUND HRH4, HRH3, HRH1 MAPT 4245/4885ALDH1A1 443/4885HTT 2048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback